Mudassir Nawaz, MD
Internal Medicine · Norman, OKNPI 1396737789
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 623 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 623 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- GSK$1K
- Amgen$903
- AstraZeneca$856
- Pfizer$777
- Novo Nordisk$593
- plus $5K from 38 others
What the payments were for
- Food & beverage$10,23899%
- Education$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,322 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $129,467 |
| EliquisApixaban | 98 | $107,794 |
| JardianceEmpagliflozin | 91 | $106,557 |
| OzempicSemaglutide | 88 | $93,330 |
| TrulicityDulaglutide | 62 | $88,883 |
| MounjaroTirzepatide | 66 | $88,416 |
| FarxigaDapagliflozin Propanediol | 95 | $78,167 |
| JanuviaSitagliptin Phosphate | 43 | $49,533 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $32,709 |
| TradjentaLinagliptin | 24 | $24,567 |
| MyrbetriqMirabegron | 29 | $22,913 |
| Repatha SyringeEvolocumab | 18 | $18,160 |
| LinzessLinaclotide | 32 | $16,805 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 17 | $15,948 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $10,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,207 | $177,299128 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Spiriva Respimat | $358 | $154,014143 claims |
| GSKTrelegy Ellipta | $1,173 | $129,467108 claims |
| PfizerEliquis | $777 | $107,79498 claims |
| Novo NordiskOzempic, Rybelsus | $593 | $102,33999 claims |
| AstraZenecaFarxiga | $856 | $78,16795 claims |
| MerckJanuvia, Janumet | $248 | $59,76156 claims |
| Astellas Pharma US IncMyrbetriq | $114 | $22,91329 claims |
| AbbVieLinzess | $451 | $16,80532 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $100 | $8,17512 claims |
| Johnson & JohnsonXarelto | $84 | $7,32713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Norman
- Elise WiesnerNorman$11K
- Sanober MalikNorman$9K
- Steve EgwuonwuLawton$464K
- Jesse RichardsTulsa$279K
- Ryan MorganOklahoma City$235K
- Madhuri LadTulsa$173K
- Stacy ChronisterTulsa$163K
- Layth Al AttarTulsa$35K
- Ali JafryOklahoma City$33K
- Gerard McNultyTulsa$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.